The Federal Trade Commission (FTC) is eyeing a tougher approach to its review of pharmaceutical mergers. The commission said in a statement Tuesday it is launching a working group with domestic and international agencies to "identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers." "This project will ensure that FTC investigations include fresh approaches that fully analyze and address the varied...